Twist Bioscience Corp. Aktie News

Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the fiscal 2026 firs...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 2:15 pm Pacific Time in San Francisco. The presentation will be webcast live and can ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders. If you currently own Twist stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-ap...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers' pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost ...

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciary duties to shareholders.

Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery customers, and NGS growth will rebound in FY27, driven by MRD customers. Twist's margins also continue to improve, and the company should start to generate positive cash flows within the next 1-2 ye...

Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but significant drops like this often prompt a more challenging question: is this weakness merely temporary, or does it indicate more profound issues in the narrative?